Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
PALO ALTO, Calif., June 15 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals' (Nasdaq: JAZZ ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms
associated with fibromyalgia, according to Phase III data presented last we...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
Long-Term Data in Patients Receiving Every-Four-Week Subcutaneous SIMPONI Presented at 2009 EULAR Annual Congress
COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) inject...
Methadone Frequently Causes Menopausal Symptoms in Young Women
TARPON SPRINGS, Fla., May 7 /PRNewswire/ -- Methadone medication frequently depresses estradiol, progesterone and testosterone hormone levels to menopausal levels, even in women less than thirty years old. Hormonal suppression, caused by methadone, can cause depression, anxiety, fatigue, weight g...
American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought
--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms
of Gastric Reflux--
WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms
such as coughing, wheezi...
Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- Atopic dermatitis, the common, chronic, inflammatory skin disease marked by red, itchy rashes, has been increasing in prevalence over the past two decades and affects a disproportionate number of children. According to current estimates, approximat...
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
First Clinical Study of Paliperidone ER in this Under-Studied Condition
SAN DIEGO, Nov. 1 /PRNewswire/ -- Patients with schizoaffective
disorder receiving paliperidone extended release tablets (paliperidone ER)
for six weeks showed a significant improvement in their symptoms, according
to a ne...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
CIMZIA(R) Data Shows Long-term Improvements in Productivity, Quality of Life and Lessened Fatigue According to Studies Presented at American College of Rheumatology (ACR) Annual Scientific Meeting
SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced
today results from se...
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
- Results of two Phase III studies affirmed the clinical benefits of
NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies
showed that patients who suffer from the debilitating and painful effects
of rheumatoid arthritis (RA) achieved significant improvements in sig...
Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease
NEW YORK, Oct. 14 /PRNewswire-USNewswire/ -- The Michael J. Fox
Foundation for Parkinson's Research awarded a total of $2 million to five
research teams to speed development of effective therapies for the
under-addressed cognitive and mood-related symptoms
of Parkinson's disease.
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
In a clinical study of adults, VYVANSE taken once-daily significantly
improved the symptoms
of ADHD within one week
PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, today
announced that a study published in th...
QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Separate survey shows high prevalence of "bothersome" vaginal atrophy
among sexually active and non-sexually active postmenopausal
women; results presented today at 19th Annual North American Menopause Society Meeting
ANN ARBOR, Mich., Sept. 24 /PRNew...
Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
Results presented at the 90th annual Endocrine Society meeting show
significant improvements among women affected by moderate to severe vaginal dryness and painful intercourse
ANN ARBOR, Mich, June 16 /PRNewswire/ -- QuatRx Pharmaceuticals today
announced detailed primary ...
Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
- Results Presented at Endocrine Society 90th Annual Meeting -
SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ --
Bionovo Inc. (Nasdaq: BNVI ) today announced results from in vitro studies
in neurons of its drug candidate, MF101. The data were presented at the
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
- Phase III monotherapy study shows ACTEMRA is first and only biologic to
demonstrate statistical superiority over methotrexate after 24 weeks of treatment -
PARIS, June 13 /PRNewswire/ -- Patients who suffer the chronic and
debilitating effects of rheumatoid arth...
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Patients Receiving Every Four-Week Subcutaneous Golimumab Also Experienced Improvements in Physical Function and Disease Activity
PARIS, June 11 /PRNewswire/ -- Findings from two new Phase 3 studies
showed that patients receiving every four-week subcutaneous injections of
QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Results presented at 12th World Congress on the Menopause show significant
improvement in vaginal dryness and dyspareunia, two of the most frequent symptoms
associated with vulvovaginal atrophy
ANN ARBOR, Mich., May 21 /PRNewswire/ -- QuatRx Pharmaceuticals today
Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
-- Clinical trial data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution presented at International ATS Conference --
NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the
International Conference of the American Thoracic Society (ATS) demonstrate
that concomitant ...
UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism
GROUNDBREAKING RESEARCH PROVIDES EVEN MORE SCIENCE SUPPORTING THE
THEORY THAT VACCINES CAN AND DO CAUSE AUTISM
NIXA, Mo., May 19 /PRNewswire-USNewswire/ -- A primate model for autism
using the U.S. children's immunization schedule was unveiled at the
International Meeting For Autism Resear...
Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
Routine Safety Study That Government Scientists Refused To Do
Illustrates Vaccine Program And Mercury Health Risks Says SafeMinds
ATLANTA, May 19 /PRNewswire-USNewswire/ -- Findings released Friday
showed that infant monkeys given vaccines officially recommended by the CDC
and the American...
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented
today at a major scientific meeting findings from analyses of pivotal trial
results of INTUNIV, a selective alpha-2A-agonist. This compound is an
Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Phase III Data Presented at American Psychiatric Association Annual Meeting
WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX ) announced today that study results show Lexapro (escitalopram
oxalate) significantly improved symptoms
of depression as compared to
Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
Additional Data Demonstrate Predictable, Extended Exposure with Sustained- Release Formulation
CHICAGO, April 17 /PRNewswire/ -- Data from the first pivotal study of
XP13512/GSK1838262, a sustained-release investigational compound to treat
Restless Legs Syndrome (RLS), ...
Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinson's Disease
Effort utilizes Phreesia's automated patient check-in system to enable better management of medication wear-off
NEW YORK, April 15 /PRNewswire/ -- Phreesia, Inc., the Patient Check-In
Company, has announced that it will integrate a new screening tool
developed by researchers at...
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
(Nasdaq: CVTX ) today announced new data presented at the 57th Annual
Scientific Sessions of the American College of Cardiology shows that
Ranexa(R) (ranolazine extended release tablets) significantly reduced the
risk of r...
MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients
Study Continues to Show Lasting Reductions in Mitral Regurgitation Across a Spectrum of Patients
CHICAGO, April 1, 2008 /PRNewswire/ -- Percutaneous mitral repair using
the MitraClip(R) device may successfully reduce mitral regurgitation (MR)
in patients suffering from f...
New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
Silent Health Issue Affects Women of All Ages
ALEXANDRIA, Va., March 19 /PRNewswire-USNewswire/ -- A study published
in the Annals of Internal Medicine (March 18, 2008) reports that pelvic
floor muscle training, in conjunction with bladder training, resolved the
symptoms of urinary incon...
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
-- Neuropsychiatric Data from Pivotal Trial Presented at Annual Meeting of American Association for Geriatric Psychiatry --
SAN FRANCISCO and ORLANDO, Fla., March 15 /PRNewswire-FirstCall/ --
Medivation, Inc. (Nasdaq: MDVN ) today announced that clinical results from
its first pivot...
Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
HOUSTON, Feb. 19 /PRNewswire/ -- A natural health company located in
Houston, Global Healing Center, Inc., announces the startling results of
recent clinical studies indicating their oxygen colon cleanser is extremely
successful at relieving symptoms
of constipation and Irritable Bowel
New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
SKILLMAN, N.J., Jan. 11 /PRNewswire/ -- According to the American
Academy of Dermatology (AAD), 10-20 percent of the world's population
suffers from eczema, an inflamed skin condition characterized by red, scaly
and itchy skin. To help manage the condition's symptoms, which tend to
flare up in...
New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
Study Also Demonstrated Significant Improvement in Eye Symptoms
DALLAS, Nov. 11 /PRNewswire/ -- Veramyst(TM) (fluticasone furoate)
Nasal Spray demonstrated significant improvement in the treatment of nasal
and ocular allergy symptoms
of perennial allergic rhinitis (PAR) in
patients 12 year...
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
NEW YORK, Nov. 8 /PRNewswire/ -- Total daily dosages of milnacipran 100
mg and 200 mg demonstrated statistically significant and clinically
meaningful improvements in both pain and other core symptoms
with fibromyalgia syndrome (FMS), according to Phase III data presented
this week ...
Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN ) today announced positive results from a Phase 2a clinical
trial of RG2417, an oral formulation of uridine, in patients with bipolar
disorder. This was a multi-center study in which 84 patients received
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
Patients with Painful and Progressive Form of Inflammatory Spinal Arthritis Receiving Monthly Golimumab Treatment Showed Marked Improvements in Physical Function
BOSTON, Nov. 7 /PRNewswire/ -- More than half of patients receiving
monthly subcutaneous (SC) injections of...
CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Two Large Phase III Trials Confirm Robust Efficacy of CIMZIA
BOSTON, Nov. 7 /PRNewswire/ -- UCB announced today the results of new
Phase III data from the RAPID 1 and 2 studies presented at the American
College of Rheumatology Annual Scientific Meeting (ACR), which show
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
ORLANDO, Fla., Oct. 13 /PRNewswire/ -- Acutely ill, hospitalized
patients with schizophrenia showed significant improvement in symptoms
after taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared
to SEROQUEL(R)(a) (quetiapine) and placebo. Symptom improvement was
observed with ...
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
COLLEGEVILLE, Pa., July 27 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced the publication in Fertility and Sterility of data from a Phase 3 clinical study that showed that the investigational compound bazedoxifene/conjugated estrogens...
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
SAN FRANCISCO, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo con...
Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Men taking generic drugs may be more likely to have less effective results and more adverse events than if they were using branded medications, according to new data from researchers in New York. Researchers presented a study at the 104th Annual ...
New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Bacillus coagulans significantly reduces abdominal pain and bloating
CLEVELAND, March 24 /PRNewswire/ -- A new study published in the March issue of Postgraduate Medicine found that a strain of probiotic bacteria, Bacillus coagulans GBI-30, PTA-6086 was effective in relieving abdominal ...
Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
EMERYVILLE, Calif., March 10 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI ) announced today results from two independent physician
surveys which showed MF101 could become first-line treatment for menopausal
(hot flashes). In both qualitative and quantitative